VV

Vangelis Vergetis

CEO, Epikast | Driven by the intersection of healthcare, data science, and technology

New York, New York

Angel
CEO
Founder
Investor

Invests in

Stages:

Seed
Series B

Locations:

  • Min Investment:

    $100,000,000.00

  • Max Investment:

    $400,000,000.00

  • Target Investment:

    $200,000,000.00

Skills

Biotechnology
Data Science
Pharmaceuticals
Healthcare
Patient Experience
Product Launch
Machine Learning
Private Equity
Growth Investing
Venture Capital
Angel Investing

Education

Lists including Vangelis

AM
AR
AG
AH

Based in NYC

2600 people

AM
AT
AS
AR

All Seed Investors

19695 people

Investments

Epikast, Inc.

Series A

Total Funding:

Intelligencia, Inc.

Angel

Total Funding:

Work Experience

E
Epikast

2022

  • CEO & Co-founder

    2022

    Epikast partners with biopharmaceutical companies as they engage their most important stakeholders: patients, physicians, and other healthcare providers.

IA
Intelligencia AI

2018 - 2024

  • Board Advisor

    2022 - 2024

  • CEO & Co-founder

    2018 - 2022

    Intelligencia's software platform utilizes Artificial Intelligence to assess the risk of clinical trials and increase R&D productivity. Partnered with top-10 pharma companies and mid-size biotechs, scaled the company to 100+ people across the US and Europe, and raised two rounds of VC financing.

H
Hakluyt

2014 - 2018

  • Partner

    2014 - 2018

M&
McKinsey & Company

2006 - 2014

  • Associate Partner, Healthcare Practice

    2006 - 2014